Market Size of Uterine Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Uterine Cancer Therapeutics & Diagnostics Market Analysis
The Uterine Cancer Therapeutics & Diagnostics Market is expected to witness a growth of 6% CAGR owing to the growing awareness of uterine cancer and increasing healthcare expenditure. In the United States, the month of September is Gynecologic Cancer Awareness Month. The American Association for Cancer Research has stated in its article that endometrial carcinoma is common across the globe whereas, Uterine Sarcoma is considered as a rare type of cancer. CDC has stated that around 68% of the uterine cancers are the endometrial carcinomas.
Furthermore, developing countries like India has a National Cancer Control Programme which was established in 1975-76. This has contributed to the development of Regional Cancer Centres (RCCs), oncology wings in medical colleges and support for the purchase of teletherapy machines. In this country, the awareness programmes about the cancer are being conducted which is making the women aware of the severity of the disease.
Looking at the severity of the disease and importance of the women health, healthcare providers along with the governments are provoking awareness programmes in certain regions such as North America, Europe, and Asia-Pacific. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly in the over the forecast period.
Uterine Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.
| By Cancer Type | |
| Endometrial Adenocarcinoma | |
| Adenosquamous Carcinoma | |
| Papillary Serous Carcinoma | |
| Uterine Sarcoma |
| By Product | |||||||
| |||||||
|
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Uterine Cancer Therapeutics & Diagnostics Market Size Summary
The Uterine Cancer Therapeutics & Diagnostics Market is poised for significant growth, driven by heightened awareness and increased healthcare spending. The market is characterized by a focus on endometrial carcinoma, which is prevalent globally, and uterine sarcoma, a rarer form of the disease. Awareness initiatives, particularly in regions like North America, Europe, and Asia-Pacific, are being spearheaded by healthcare providers and governments to educate women about the severity of uterine cancer. In developing countries such as India, national programs have been established to enhance cancer control efforts, including the creation of Regional Cancer Centres and oncology wings in medical colleges. These initiatives are contributing to the market's expansion, as they promote early detection and treatment options.
The market's growth is further fueled by the increasing incidence of endometrial adenocarcinoma, the most common type of uterine cancer, and the rising obesity rates among women, which are linked to the disease's prevalence. North America is expected to lead the global market due to the high incidence of uterine cancer and the rapid adoption of advanced diagnostic technologies. The competitive landscape is moderately populated with global players, although smaller companies are also making strides in market penetration. Key industry participants include Abbott Laboratories, Becton Dickinson and Company, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and GlaxoSmithKline Plc, all of which are contributing to the market's dynamic growth trajectory.
Uterine Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
-
1.2.2 Increasing Health Care Expenditure
-
1.2.3 Innovation in Drug Development and Subsequent Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
-
1.3.2 High Cost Associated With the Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Endometrial Adenocarcinoma
-
2.1.2 Adenosquamous Carcinoma
-
2.1.3 Papillary Serous Carcinoma
-
2.1.4 Uterine Sarcoma
-
-
2.2 By Product
-
2.2.1 Therapeutics
-
2.2.1.1 Surgery
-
2.2.1.2 Immunotherapy
-
2.2.1.3 Radiation Therapy
-
2.2.1.4 Chemotherapy
-
2.2.1.5 Others
-
-
2.2.2 Diagnostics
-
2.2.2.1 Biopsy
-
2.2.2.2 Pelvic Ultrasound
-
2.2.2.3 Hysteroscopy
-
2.2.2.4 Dilation and Curettage
-
2.2.2.5 CT Scan
-
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Uterine Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current Uterine Cancer Therapeutics & Diagnostics Market size?
The Uterine Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 6% during the forecast period (2024-2029)
Who are the key players in Uterine Cancer Therapeutics & Diagnostics Market?
Abbott Laboratories, Becton Dickinson and Company, Merck & Co., Inc., Takeda Pharmaceutical Company Limited and GlaxoSmithKline Plc. are the major companies operating in the Uterine Cancer Therapeutics & Diagnostics Market.
